SAS Output

20-AUG-2018 6:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1755 401 236 107 33 6 07/08/2014 461 225
            1755 401 236 107 33 6      
 
    2 Y 17 S1400G   63 33 18 2 0 0      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        21 S1400F   80 80 53 27 9 2      
        25 S1400K   46 46 46 21 6 1      
        3 S1400B   53 0 0 0 0 0      
        4 S1400C   88 0 0 0 0 0      
        5 S1400D   92 0 0 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   700 105 20 0 0 0      
            1298 264 137 50 15 3      
 
    3 P 10 S1400I   13 6 3 0 0 0      
        18 S1400G   10 4 2 0 0 0      
        22 S1400F   23 23 17 9 5 2      
        8 S1400B   1 0 0 0 0 0 07/08/2014    
            47 33 22 9 5 2      
 
    4 P 23 S1400F   3 3 2 1 0 0 07/08/2014    
            3 3 2 1 0 0      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014    
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 4 1 0 0 0 0 07/31/2014    
            4 1 0 0 0 0      
 
  S1400F-Non-Match: MEDI4736 + Tremelimumab 1 Y 1 MEDI4736 + Tremelimumab 132 28 28 17 11 5 0 11/30/2017 484 229
            28 28 17 11 5 0      
 
  S1400K-c-Met: ABBV-399 (Process II) 1 Y 1 ABBV-399 (Process II) 44 26 26 26 13 5 0 03/16/2018 461 220
            26 26 26 13 5 0      
 
  S1619-Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 1 Y 1 Chemotherapy + Atezolizumab 28 4 4 4 4 3 0 07/16/2018 72 21
            4 4 4 4 3 0      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 N 5 RT+Pac+Carbo+blinded drug 132 18 2 0 0 0 0 01/24/2013 29 13
        6 RT+Pac+Carbo+blinded drug   14 2 0 0 0 0      
            32 4 0 0 0 0      
 
    2 Y 8 Pac + Carbo + blinded drug 132 23 9 0 0 0 0 01/24/2013    
            23 9 0 0 0 0      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   40 15 7 1 0 0 04/01/2015 488 253
            40 15 7 1 0 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   578 234 134 74 30 7 12/16/2014 478 250
            578 234 134 74 30 7      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   56 4 1 0 0 0 05/14/2008 209 109
            56 4 1 0 0 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   9 5 2 1 1 0 02/29/2016 473 252
            9 5 2 1 1 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   4 1 0 0 0 0 10/20/2016 319 140
            4 1 0 0 0 0      
 
    2 E Total Registrations   4 1 0 0 0 0 10/20/2016    
            4 1 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   585 235 135 75 30 8 12/16/2014 478 250
            585 235 135 75 30 8      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   64 47 28 18 5 2 08/03/2016 448 242
            64 47 28 18 5 2      
 
  EA5161-Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo 1 E Total Registrations   2 2 2 2 0 0 06/26/2018 87 35
            2 2 2 2 0 0      
 

20-AUG-2018 6:10

LUNG Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 2 Surgery 03-Nov-17
  3 Maintenance 03-Nov-17
S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac 1 Randomization 09-Aug-18